What topics does this cannabis study cover?

This study covers research on: Epilepsy, CBD.

Where was this research published?

Published in Current neuropharmacology on April 16, 2026.

CBD shows promise in genetic epilepsy treatment breakthrough

Potassium Channelopathies and Precision Medicine Approaches in Epilepsy: A Systematic Review of Personalized Treatment Strategies.

Current neuropharmacology • April 16, 2026 • Moderately Relevant

🤖

AI Summary

This systematic review examines how precision medicine can tailor treatments for epilepsy caused by mutations in potassium channel genes. After analyzing over 2,200 studies, researchers identified 60 relevant papers examining different genetic variants and their responses to various therapies. The findings reveal that some cannabinoid and non-cannabinoid treatments show promise for specific genetic subtypes of epilepsy, offering hope for patients who haven't responded to conventional antiepileptic drugs.

For patients with KCNT1 variants—the most studied gene variant with 38 studies—several treatments including cannabidiol (CBD), quinidine, fluoxetine, and carvedilol have shown effectiveness in some patients. The research highlights CBD as a potential therapy across multiple genetic epilepsy types, including KCNT1, KCNQ2, and KCNB1 variants. This finding is particularly significant because it suggests cannabinoids may work through specific biological mechanisms related to potassium channel dysfunction, rather than just general seizure suppression.

While the review provides valuable guidance for clinicians selecting personalized treatments, the authors acknowledge limitations in evidence quality and heterogeneous data across studies. The precision medicine approach shows that different genetic epilepsies require different treatment strategies—a paradigm shift from one-size-fits-all antiepileptic drugs. This framework could revolutionize how neurologists approach drug-resistant epilepsy, potentially improving outcomes for patients with rare genetic forms of the condition.

📄 Original Abstract

This systematic review aimed to summarize recent progress in precision medicine for all studied potassium gene variants related to epilepsy. It analyzed studies conducted in cell and animal models and in humans. A comprehensive search was conducted on PubMed, Embase, and Cochrane databases for all years up to 2025. Approximately 2257 papers were reviewed, but only 60 met the inclusion criteria: KCNT1 [n = 38], KCNQ2 [n = 10], KCNQ5 [n = 1], KCNB1 [n = 1], KCNA2 [n = 3], KCNA1 [n = 2], KCNA3 [n = 1], KCNT2 [n = 2], and KCNC1 [n = 2]. Therapies that appear effective for some patients with KCNT1 variants include quinidine, cannabidiol, fluoxetine, and carvedilol. Potential treatments supported by cell and/or animal models include bepridil and antisense oligonucleotide therapy. There is currently no precision therapy for KCNT2 variants; however, potential treatments supported by cell model evidence include quinidine, fluoxetine, loxapine, and riluzole. Emerging potential therapies for KCNQ2-related epilepsy include ezogabine, gabapentin, retigabine, donepezil, amitriptyline, linopirdine, pynegabine, SF0034, and XEN1101. Retigabine and gabapentin are potential therapies for KCNQ5 variants. Cannabidiol is a potential therapy for KCNB1 variants. 4-Aminopyridine is useful for KCNA1 and KCNA2 variants. Gapmer antisense oligonucleotides are a potential treatment for KCNA2 variants. Fluoxetine is a potential therapy for KCNA3 variants. Fluoxetine and compound RE01 are the potential therapies for KCNC1 variants. These studies collectively offer valuable insights into precision medicines for genetic epilepsy caused by pathogenic potassium variants. This review is essential because it informs clinical decision-making, including the selection of antiepileptic drugs, thereby supporting its integration into routine clinical care for this population. However, the low level of evidence and the heterogeneity of data from the included studies limit the review.

Paper Type

📄 Research

Publication

Journal: Current neuropharmacology
Published: April 16, 2026
PMID: 42003125
DOI: 10.2174/011570159X407197251204124232

Authors (4)

Changning Xie Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Fei Yin Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Miriam Kessi Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Jing Peng Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.